MNG784
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.462
- INTERFERON_ALPHA_RESPONSE+0.455
- INTERFERON_GAMMA_RESPONSE+0.449
- OXIDATIVE_PHOSPHORYLATION+0.332
- MYC_TARGETS_V2+0.329
- MYC_TARGETS_V1+0.306
- PROTEIN_SECRETION+0.275
- INFLAMMATORY_RESPONSE+0.270
- DNA_REPAIR+0.247
- IL6_JAK_STAT3_SIGNALING+0.235
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.374
- APICAL_SURFACE-0.330
- APICAL_JUNCTION-0.329
- ANGIOGENESIS-0.264
- CHOLESTEROL_HOMEOSTASIS-0.256
- ESTROGEN_RESPONSE_EARLY-0.245
- ESTROGEN_RESPONSE_LATE-0.224
- WNT_BETA_CATENIN_SIGNALING-0.224
- MYOGENESIS-0.206
- PANCREAS_BETA_CELLS-0.178
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-A61S-01A-11R-A28V-07 | — | — | 0.794 |
| 2 | 45a2676b-25ba-41b0-9e55-08c6eb3a8f2f | — | — | 0.791 |
| 3 | MNG632 | — | — | 0.787 |
| 4 | a88a1582-88b8-4e7e-9baf-09279b49a492 | — | — | 0.778 |
| 5 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.765 |
| 6 | TCGA-T2-A6WX-01A-12R-A34R-07 | — | — | 0.756 |
| 7 | fe769a85-08b2-4442-aa8f-2b587e49001d | — | — | 0.752 |
| 8 | GSM6454734 | — | D | 0.749 |
| 9 | MNG1169 | — | — | 0.747 |
| 10 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.462 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.455 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.449 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.332 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.329 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.306 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.275 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.247 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.235 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.201 | Idelalisib | — uncovered |
| PEROXISOME | 0.135 | Idelalisib | — uncovered |
| COMPLEMENT | 0.134 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.116 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.108 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.098 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.076 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.057 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.052 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.026 | Inavolisib | — uncovered |